Free delivery for orders over 69.99 euro

Check order status

Become part of a community of book lovers from all over the world and get access to a whole bunch of benefits. Create an account for free

Free delivery for purchases over 69.99 €

DPD courier 3.99 € DPD point 3.49 € GLS courier 4.99 € GLS point 3.99 € Croatian Post 4.99 € Overseas courier 4.99 € Box Now 4.49 €

Contact

How to shop

Help

My account

▸ Empty :-(

Free delivery for orders over 69.99 euro

Developments in T Cell Based Cancer Immunotherapies

Name: Developments in T Cell Based Cancer Immunotherapies
Brand: Springer International Publishing AG
SKU: 09361537
Price: 153.47 EUR
Availability: InStock
Author: Ena Wang
ISBN: 9783319211664

Ena Wang

Paolo A. Ascierto

David F. Stroncek

Language

English

Book Hardback

Libristo code: 09361537

Publishers Springer International Publishing AG, November 2015

This volume illustrates the salient aspects of cancer biology relevant to the successful implementat... Full description

Libristo code: 09361537

373 b

153.47 €

In stock at our supplier Shipping in 10-13 days

Up to 30 days for returns

Customers also purchased

Nur ein Amoklaufer? - Sozialpsychologische Zeitdiagnose nach Erfurt Richard Albrecht

Paperback

16.08 €

Hausmittel für die ganze Familie Cosima Bellersen Quirini

Paperback

15.18 €

Consumerisme Mediatique Et Processus Democratique En Cote d'Ivoire Agney-F

Paperback

48.67 €

Grundbuchordnung Peter Gantzer

Hardback

108.61 €

Chuť ticha Štefánia Baranová

Hardback

6.02 €

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.